Royal Bank Of Canada Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $677.00

United Therapeutics (NASDAQ:UTHR) had its target price dropped by research analysts at Royal Bank Of Canada from $704.00 to $677.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 28.49% from the company’s current price.

A number of other research firms have also recently commented on UTHR. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, July 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Trading Up 1.5%

Shares of United Therapeutics stock traded up $7.90 during trading hours on Thursday, reaching $526.91. The stock had a trading volume of 601,246 shares, compared to its average volume of 487,208. The stock’s 50 day moving average is $540.37 and its 200 day moving average is $533.71. United Therapeutics has a twelve month low of $292.34 and a twelve month high of $609.35. The firm has a market capitalization of $22.37 billion, a PE ratio of 19.48, a PEG ratio of 1.73 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 EPS. As a group, sell-side analysts predict that United Therapeutics will post 26.65 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $167,432,054.58. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jan Malcolm sold 325 shares of the firm’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $550.59, for a total transaction of $178,941.75. Following the completion of the sale, the director owned 450 shares in the company, valued at $247,765.50. The trade was a 41.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 474,533 shares of company stock valued at $261,703,072 in the last 90 days. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new stake in United Therapeutics in the 2nd quarter valued at about $159,522,000. Focus Partners Advisor Solutions LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at about $795,000. S&CO Inc. acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $775,000. Handelsbanken Fonder AB increased its stake in shares of United Therapeutics by 4.1% during the 2nd quarter. Handelsbanken Fonder AB now owns 13,120 shares of the biotechnology company’s stock worth $7,109,000 after purchasing an additional 520 shares in the last quarter. Finally, PensionDanmark Pensionsforsikringsaktieselskab increased its stake in shares of United Therapeutics by 7.4% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company’s stock worth $5,992,000 after purchasing an additional 760 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics reported second-quarter adjusted earnings of $7.27 per share, exceeding analyst expectations of approximately $6.82–$6.86 and rising from $6.41 a year earlier. The earnings beat supports the stock by highlighting strong profitability and operating leverage. United Therapeutics Q2 Earnings Surpass Estimates
• Positive Sentiment: The company said it submitted regulatory applications for ralinepag and another important pulmonary-disease program. Investors view the pipeline as a potential source of longer-term growth that could diversify United Therapeutics beyond its current pulmonary arterial hypertension products. United Therapeutics Reports Second-Quarter 2026 Results
• Neutral Sentiment: Management’s earnings call balanced near-term Tyvaso-related challenges with progress in ralinepag and other development programs. This creates a mixed outlook: established-product performance remains a concern, but successful pipeline execution could reshape future growth. United Therapeutics Balances Tyvaso Woes With Pipeline Wins
• Negative Sentiment: Second-quarter revenue was $783.3 million, below the roughly $804.7 million consensus estimate and down about 2% year over year. The revenue miss indicates softer demand or product pressure despite the EPS beat, limiting the positive earnings reaction. United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares worth approximately $4.9 million. Although the sale reduced her direct holdings by only 2.84% and may have been routine, insider selling can add modestly to investor caution. United Therapeutics CEO Sells Stock

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.